Pre-test
The Role of Novel Methylphenidate Formulations in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
1. What is your profession?
Please answer ...
a. Physician
b. Physician Assistant
c. Nurse Practitioner
d. Nurse
e. Other
If Other, please specify:
2. What is your specialty?
Please answer ...
a. Psychiatry
b. Pediatrics
c. Internal Medicine
d. Family Medicine
e. General Medicine
Other
If Other, please specify:
3. Which of the following is a serdexmethylphenidate and dexmethylphenidate combination capsule?
Please answer ...
a. Azstarys®
b. Cotempla XR-ODT®
c. Daytrana®
d. Jornay PM®
4. Which of the following is a medication that is taken at night that begins to work in the early morning that has a duration of effect of 12 hours?
Please answer ...
a. Azstarys®
b. Cotempla XR-ODT®
c. Daytrana®
d. Jornay PM®
5. Which of the following formulations is a transdermal patch?
Please answer ...
a. Azstarys®
b. Cotempla XR-ODT®
c. Daytrana®
d. Jornay PM®
6. Which of the following formulations is an extended-release tablet formulation of methylphenidate?
Please answer ...
a. Azstarys®
b. Relexxii®
c. Daytrana®
d. Jornay PM®
7. Which of the following is not a possible side effect of methylphenidate formulations?
Please answer ...
a. Decreased appetite
b. Weight gain
c. Tremor
d. Tachycardia
e. Increased blood pressure
First Name:
Required
Last Name:
Required
Specialty:
Please make a selection
MD
DO
PA
NP
RN
Pharmacist
PA/PA-C
Other
If Other, please specify: